Butterfly Medical, developer of a proprietary non-surgical solution for BPH (benign prostatic hyperplasia), today announced ...
Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker ...
The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for commercialisation.
PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to ...
Andera Partners, a leading European venture capital and private equity firm, today announced it led a $20 million Series D financing in Rivermark Medical, Inc., a urology-focused medical device ...
Baptist Health System now offers aquablation therapy for men with benign prostatic hyperplasia or BPH, a health issue that becomes more common with age. The advertiser paid a fee to promote this ...
The medication vibegron led to improvements in symptoms of overactive bladder and overall quality of life in men undergoing treatment for benign prostatic hyperplasia, according to findings from a ...
Benign Prostatic Hyperplasia Surgical Treatment Market OverviewThe global benign prostatic hyperplasia surgical treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results